Background: Single pegylated liposomal doxorubicin (PLD) is commonly used as a salvage treatment inplatinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma (PPA) with asatisfactory outcome. However, the data for second generation PLD administered in this setting are still limited.We conducted a retrospective study to evaluate the outcome of patients who received single-agent secondgeneration PLD (LIPO-DOX) after the development of clinical platinum resistance. The study period was betweenMarch 2008 and March 2013. LIPO-DOX was administered intravenously 40 mg/m2 every 28 days until diseaseprogression, but for not more than six cycles. The response rate was evaluated using the Gynecologic CancerIntergroup (GCIG) criteria while the toxicity was evaluated according to WHO criteria. Twenty-nine patientsmet the inclusion criteria in the study period with an overall response rate of 13.8%. The median progressionfree survival and overall survival were three and eleven months, respectively. With the total of 96 cycles ofchemotherapy, the patients developed grades 3 and 4 hematologic toxicity as follows: anemia, 0%, leukopenia,9.6%, neutropenia, 32.3% and thrombocytopenia, 0%. In conclusion, the single agent second generation PLDdemonstrated modest efficacy in patients with platinum-resistant ovarian cancer, fallopian tube cancer and PPAwithout serious toxicity.